Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis.

Antonio FacciorussoIrene BargelliniMarina CelaIvan CincioneRodolfo Sacco

Published in: Cancers (2020)

The association of sorafenib does not prolong survival nor delay progression in patients treated with radioembolization. Liver toxicity does not differ among the two therapeutic schemes.

Keyphrases

liver metastases
oxidative stress
free survival
replacement therapy
smoking cessation